• Josip Mihić, Krešimir Rotim, Majda Vučić, Ida Hude Dragičević, Marta Borić, and Liborija Lugović-Mihić.
• 1Department of Neurosurgery, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia; 2Department of Pathology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia; 3Division of Hematology, Department of Internal Medicine, Zagreb University Hospital Centre, Zagreb, Croatia; 4Department of Dermatovenereology, Allergy and Clinical Immunology Unit, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia.
• Acta Clin Croat. 2019 Sep 1; 58 (3): 455-462.

AbstractGlioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. Clinically useful molecular markers that help predict response to therapy and prognosis are still rare. The research was conducted in 55 patients with GBM, 26 (47.3%) women and 29 (52.7%) men, mean age 62.58 years. On immunohistochemical analysis, primary antibody to CD44 (dilution 1:50) and primary antibody to endoglin (CD105) (dilution 1:250) were used to evaluate neovascularization. Statistical analysis showed negative correlation between CD44 and survival (p=0.023) (higher expression of CD44 was correlated with shorter survival), but there was no correlation between neovascularization determined by CD105 in GBM and patient survival. Thus, significant individual predictors of longer survival were lower expression of CD44 (p=0.004), higher Karnofsky score (p=0.045), and female gender (p=0.017). The results obtained suggested the possible role of CD44 in the progression and tumor neovascularization of GBM.

29 keywords...

hide…